Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05094804
Title A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors OncoResponse, Inc.
Indications

sarcoma

Advanced Solid Tumor

melanoma

lung non-small cell carcinoma

triple-receptor negative breast cancer

carcinoma

head and neck squamous cell carcinoma

Therapies

Nivolumab + OR2805

OR2805 + Pembrolizumab

OR2805

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.